# Aranzazu Fernandez-Martinez

List of Publications by Year
in descending order

| 21 papers | 793 citations | 933447 10 h-index | 888059 17 g-index |
|---|---|---|---|
| 21 all docs | 21 docs citations | 21 times ranked | 1037 citing authors |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1 | Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Npj Breast Cancer, 2021, 7, 1. | 5.2 | 331 |
| 2 | HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 84, 101965. | 7.7 | 92 |
| 3 | Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treatment Reviews, 2018, 67, 63-70. | 7.7 | 79 |
| 4 | Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology, 2020, 38, 4184-4193. | 1.6 | 74 |
| 5 | CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1323-1334. | 1.6 | 62 |
| 6 | Outpatient Management of Pulmonary Embolism in Cancer: Data on a Prospective Cohort of 138 Consecutive Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 365-373. | 4.9 | 38 |
| 7 | Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Clinical and Translational Oncology, 2017, 19, 119-124. | 2.4 | 23 |
| 8 | Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. Future Oncology, 2016, 12, 2683-2688. | 2.4 | 17 |
| 9 | Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. Oncotarget, 2017, 8, 21930-21937. | 1.8 | 17 |
| 10 | Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. Frontiers in Oncology, 2019, 9, 1178. | 2.8 | 10 |
| 11 | Prognostic value of 18F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2016, 35, 88-95. | 0.0 | 9 |
| 12 | Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy. Clinical Cancer Research, 2021, 27, 3116-3125. | 7.0 | 9 |
| 13 | A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Frontiers in Oncology, 2019, 9, 303. | 2.8 | 8 |
| 14 | Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. ESMO Open, 2016, 1, e000032. | 4.5 | 7 |
| 15 | Pembrolizumab in a *BRAF*-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. Immunotherapy, 2016, 8, 687-692. | 2.0 | 7 |
| 16 | Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. Journal of Clinical Oncology, 2019, 37, 571-571. | 1.6 | 6 |
| 17 | Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.. Journal of Clinical Oncology, 2022, 40, 509-509. | 1.6 | 4 |
| 18 | Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma. Annals of Oncology, 2015, 26, viii5. | 1.2 | 0 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 19 | Phlegmasia cerulea dolens and multiple recurrent thrombotic events as the presenting feature of EML4-ALK translocated non-small cell lung cancer. Cancer Treatment Communications, 2016, 6, 4-7. | 0.4 | 0 |
| 20 | Venous Thromboembolism in Cancer Patients: Comparison of Lung Cancer Patients to Other Solid Tumor Patients in a Prospective Observational Study. Advances in Cancer: Research & Treatment, 2013, , 1-12. | 0.0 | 0 |
| 21 | Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.. Journal of Clinical Oncology, 2017, 35, 66-66. | 1.6 | 0 |